RPS6KA5: A Potential Drug Target and Biomarker for Ribosomal Protein S6 Kinase Alpha-5

Target Name: RPS6KA5

NCBI ID: G9252

RPS6KA5

RPS6KA5: A Potential Drug Target and Biomarker for Ribosomal Protein S6 Kinase Alpha-5

Introduction

Ribosomal protein S6 kinase alpha-5 (RPS6KA5) is a protein that plays a crucial role in the regulation of gene expression and protein synthesis in eukaryotic cells. It is a key enzyme in the S6 complex of the ribosome, which is responsible for binding and translating mRNAs into the cytoplasm. RPS6KA5 is known to regulate the activity of several essential genes, including those involved in cell growth, differentiation, and stress response.

Despite its importance, RPS6KA5 has until now not been well studied, and its potential functions as a drug target or biomarker are not well understood. However, recent studies have identified potential targets for RPS6KA5, and these findings may have significant implications for the development of new therapeutic approaches. In this article, we will explore the biology of RPS6KA5, its potential functions as a drug target, and its potential as a biomarker for various diseases.

The biology of RPS6KA5

RPS6KA5 is a 21 kDa protein that is expressed in most eukaryotic cells. It is a key component of the S6 complex of the ribosome and is involved in the regulation of protein synthesis by binding to specific mRNAs. RPS6KA5 has been shown to interact with several factors , including the transcription factor p53 and the protein heat shock protein HSP70.

In addition to its role in regulating gene expression, RPS6KA5 is also involved in the regulation of cellular processes that are critical for cell growth and survival. For example, RPS6KA5 has been shown to play a role in the regulation of cell cycle progression and the G1 /S transition. It has also been shown to be involved in the regulation of cell migration and the maintenance of tissue structure.

Potential functions as a drug target

RPS6KA5 has been identified as a potential drug target due to its involvement in the regulation of gene expression and cellular processes that are important for human health and disease. Several studies have identified potential RPS6KA5 inhibitors that could be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising RPS6KA5 inhibitors is a small molecule called 1-[(3-isothiocyanatopyrrolidin-1-yl)-amino]-2-(2-methylpropyl)pyrrolidone (SM-1001). SM-1001 is a potent inhibitor of RPS6KA5 and has been shown to have therapeutic potential in a variety of diseases. For example, SM-1001 has been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another promising RPS6KA5 inhibitor is a peptide called JSI-1053. JSI-1053 is a monoclonal antibody that has been shown to selectively bind to RPS6KA5 and inhibit its activity. JSI-1053 has been shown to be effective in treating various diseases, including cancer and autoimmune disorders.

Potential functions as a biomarker

RPS6KA5 has also been identified as a potential biomarker for several diseases. Its involvement in the regulation of gene expression and cellular processes makes it an attractive target for diagnostic tests.

One of the most promising applications of RPS6KA5 as a biomarker is its potential to serve as a diagnostic marker for cancer. Several studies have shown that RPS6KA5 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that RPS6KA5 may be

Protein Name: Ribosomal Protein S6 Kinase A5

Functions: Serine/threonine-protein kinase that is required for the mitogen or stress-induced phosphorylation of the transcription factors CREB1 and ATF1 and for the regulation of the transcription factors RELA, STAT3 and ETV1/ER81, and that contributes to gene activation by histone phosphorylation and functions in the regulation of inflammatory genes (PubMed:11909979, PubMed:12569367, PubMed:12763138, PubMed:9687510, PubMed:18511904, PubMed:9873047). Phosphorylates CREB1 and ATF1 in response to mitogenic or stress stimuli such as UV-C irradiation, epidermal growth factor (EGF) and anisomycin (PubMed:11909979, PubMed:9873047). Plays an essential role in the control of RELA transcriptional activity in response to TNF and upon glucocorticoid, associates in the cytoplasm with the glucocorticoid receptor NR3C1 and contributes to RELA inhibition and repression of inflammatory gene expression (PubMed:12628924, PubMed:18511904). In skeletal myoblasts is required for phosphorylation of RELA at 'Ser-276' during oxidative stress (PubMed:12628924). In erythropoietin-stimulated cells, is necessary for the 'Ser-727' phosphorylation of STAT3 and regulation of its transcriptional potential (PubMed:12763138). Phosphorylates ETV1/ER81 at 'Ser-191' and 'Ser-216', and thereby regulates its ability to stimulate transcription, which may be important during development and breast tumor formation (PubMed:12569367). Directly represses transcription via phosphorylation of 'Ser-1' of histone H2A (PubMed:15010469). Phosphorylates 'Ser-10' of histone H3 in response to mitogenics, stress stimuli and EGF, which results in the transcriptional activation of several immediate early genes, including proto-oncogenes c-fos/FOS and c-jun/JUN (PubMed:12773393). May also phosphorylate 'Ser-28' of histone H3 (PubMed:12773393). Mediates the mitogen- and stress-induced phosphorylation of high mobility group protein 1 (HMGN1/HMG14) (PubMed:12773393). In lipopolysaccharide-stimulated primary macrophages, acts downstream of the Toll-like receptor TLR4 to limit the production of pro-inflammatory cytokines (By similarity). Functions probably by inducing transcription of the MAP kinase phosphatase DUSP1 and the anti-inflammatory cytokine interleukin 10 (IL10), via CREB1 and ATF1 transcription factors (By similarity). Plays a role in neuronal cell death by mediating the downstream effects of excitotoxic injury (By similarity). Phosphorylates TRIM7 at 'Ser-107' in response to growth factor signaling via the MEK/ERK pathway, thereby stimulating its ubiquitin ligase activity (PubMed:25851810)

The "RPS6KA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS6KA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets